Novartis First-Generation Lung Cancer Drug Tweaked To Reduce Potential Side Effects

Medicinal Chemistry: Redesigned enzyme inhibitor designated as breakthrough therapy by FDA



via Chemical & Engineering News: Biological SCENE http://feedproxy.google.com/~r/biological_scene/~3/ujIVvqkN7UY/Novartis-First-Generation-Lung-Cancer.html